Fox Chase Chemical Diversity Center Inc.

Fox Chase Chemical Diversity Center Inc., a for-profit Subchapter S corporation headquartered in Doylestown, Pennsylvania, delivers drug discovery and chemical probe development services to the National Institutes of Health and related federal health research agencies primarily as a prime grant recipient (85% of recent awards), with a smaller subcontract footprint supporting university-led research initiatives. The vendor operates in full-and-open federal grant competitions with no SBA designations.

Fox Chase's customer concentration is heavily weighted to NIH intramural programs. The top five funding entities account for 77% of recent awards, dominated by the National Institute of Allergy and Infectious Diseases (16 awards, $307 thousand combined potential value), followed by generic NIH funding, the National Heart, Lung, and Blood Institute (six awards), and the National Cancer Institute (three awards). All five top-customer slots fall within the Department of Health and Human Services and its NIH component, reflecting Fox Chase's positioning as a specialized life-sciences research organization working with federal biomedical agencies.

Fox Chase's prime work centers on computational chemistry, virtual screening, medicinal chemistry, and structure-activity relationship (SAR) development for infectious disease, neurodegenerative disease, and antimicrobial-resistance research. Representative awards include a $1.07 million National Institute on Aging Project Grant (awarded March 1, 2026, completion targeted November 30, 2030) for AI and machine-learning-driven discovery of in vivo chemical probes for understudied Alzheimer's disease targets, working within the TREAT-AD consortium; a $306,500 SBIR Topic 134 definitive contract from the National Institute of Allergy and Infectious Diseases (awarded November 15, 2024, completion November 14, 2025); and two prior NIAID Project Grants for host-oriented small-molecule therapeutics targeting SARS-CoV-2 (awarded August 22, 2022, completion July 31, 2025) and FOSA inhibitors to potentiate fosfomycin activity in gram-negative pathogens (awarded August 15, 2022, completion June 30, 2024). Across this work, Fox Chase delivers chemical synthesis, computational modeling, ADME (absorption, distribution, metabolism, excretion) assessment, and medicinal chemistry support.

In its subcontract role, Fox Chase partners with Duke University, Louisiana State University, Temple University, the University of Pennsylvania, and Thomas Jefferson University as a medicinal chemistry and chemical synthesis sub-recipient on NIH-funded projects led by those institutions. Recent sub work includes synthesis of DART reagents for a Duke University project (awarded October 1, 2025), preparation of iron-homeostasis-targeting analogs for an LSU project (awarded March 11, 2025 and February 29, 2024), synthesis and supply of Troriluzole for substance-abuse research at Temple University (awarded July 1, 2024), genomics and molecular biology support for lymphoma research at the University of Pennsylvania (awarded April 12, 2024 and December 23, 2023), and hit triage and medicinal chemistry diversification for Thomas Jefferson University tuberculosis research (awarded March 19, 2024). The vendor staffs these projects with MS-level medicinal chemists and PhD-level computational and structural biologists; named personnel include key contributors Reitz, Kulp, Parker, Ye, and McDonnell.

Activity has been sparse but recent — two awards in 2022, one in 2023, five in 2024, two in 2025, and one in 2026 — with only three awards facing ultimate completion within the next twenty-four months. The source reports combined obligated dollars of $83.1 million across the award portfolio, a figure substantially larger than the combined potential value of $307 thousand, indicating substantial prior invoiced revenue and multi-year performance history not fully captured in the recent award snapshot. Fox Chase competes exclusively in open federal research grant competitions without set-aside advantages.